The specter of generic rivalry has consistently loomed around copyright’s famous drug, Sildenafil, triggering questions about the outlook of similar drug investments. While first years saw substantial returns, the intellectual property end has opened the path for less expensive copies, possibly reducing earnings and creating a genuine hazard for